Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label nivolumab study in relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant
NL-OMON47502Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in classical Hodgkin lymphoma (cHL) (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Overall response rate by independent review. Started Sep 2014; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON47502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47502.